trending Market Intelligence /marketintelligence/en/news-insights/trending/yxzicibuhy5rvmhh6oc8ma2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Exelixis plans US drug application on positive cancer treatment results

How 37 Years of Default Data Can Prepare Us for the COVID-19 Fallout

US Pushes Pedal To The Metal On Broadband Speeds Ahead Of COVID-19 Outbreak

Broadband-Only Homes Surge To 25% Of US Households Ahead Of COVID-19 Crisis

Pandemic Causing Wildly Different Outcomes Across Media Sectors

Exelixis plans US drug application on positive cancer treatment results

Exelixis Inc. said Oct. 10 its cabozantinib drug performed better against sunitinib in treating advanced kidney cancer, prompting the company to plan an application for the treatment in the U.S.

Results from randomized phase two trial with patients suffering from previously untreated advanced renal cell carcinoma showed cabozantinib decreasing rate of disease progression or death by 31% when compared to sunitinib, which is marketed by Pfizer Inc

Exelixis and partner Ipsen will jointly host a live webcast at 1 p.m. ET on Oct. 10 to discuss the study and its data.